Reportedly, JJohnson & Johnson (JNJ) along with its Janssen Pharmaceutical Companies have entered a settlement agreement with the Ohio counties of Cuyahoga and Summit settling all the claims for a combined payment of $10 million with no further admission of liability. The settlement has also removed the company from the federal trial which was scheduled to begin October 21, 2019. J&J who claims to be actively participating and helping communities to meet Opioid crisis has also agreed to reimburse counties legal and other expenses incurred in preparation for the trial at $5 million. Additionally, the company will contribute $5.4 million to non-profit organizations working for the Opioid-related cases in the above two counties.
J&J claimed to be open to take appropriate and corrective actions for the overall opioid litigation in the country. The company defended to have responsibility marketed DURAGESIC®, NUCYNTA®, and NUCYNTA® ER which accounting for less than one percent of the total opioid crisis int the country.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive!
Post View Count : 770